(1.2%) receiving dacarbazine; cardiomyopathy leading to death occurred in 1 patient (0.3%) receiving YONDELIS®and in none of the patients receiving dacarbazine. The median time to development of Grade 3 or 4 cardiomyopathy in patients receiving YONDELIS®was 5.3 months (range: 26 days to ...
Janssen CarePath Janssen CarePathis becoming J&J withMe.Our name may be changing, but our commitment to patients stays the same.Learn MoreX Welcome toJanssen CarePath Janssen CarePath INVEGA SUSTENNA® Support to help your patients start and stay on medication...
Janssen CarePath Janssen CarePathis becoming J&J withMe.Our name may be changing, but our commitment to patients stays the same.Learn MoreX Welcome toJanssen CarePath Janssen CarePath INVEGA HAFYERA™ Support to help your patients start and stay on medication...
Janssen CarePath is becoming J&J withMe. Our name may be changing, but our commitment to patients stays the same. Learn More X For Healthcare Professionals For Patients & Caregivers Important Safety Information Prescribing Information 877-CarePath (877-227-3728)...
Janssen CarePath INVEGA SUSTENNA® Treatment Support We understand that you want to get your patients the help they may need while going through treatment. That’s why we’ve put together some support resources that can help them, whether they’re just starting a new medication or they’ve ...
What’s next? Writing the prescription is just the first step in starting a patient on OPSYNVI®. Next, the patient's healthcare team must complete and submit the relevantforms. ThePATHwatch® Portalis also a helpful tool for submitting and tracking certain documents. ...